secwatch.observer — SEC 8-K summary
======================================

Issuer:     IDEXX LABORATORIES INC /DE (IDXX)
CIK:        0000874716
Form:       8-K
Filed at:   2025-02-03T23:59:59+00:00
Accession:  0001104659-25-008331
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

IDEXX Q4 revenue $954M (+6% YoY), EPS $2.62; guides 2025 rev $4.06-$4.17B, EPS $11.74-$12.24
--------------------------------------------------------------------------------

- Q4 revenue $954M (+6% reported and organic); CAG Diagnostics recurring revenue +7% organic.
- Q4 EPS $2.62 (+13% as reported, +10% comparable); full year EPS $10.67 (+12% comparable).
- 2025 revenue guidance $4.055-$4.170B (+4-7% reported, +6-9% organic); EPS $11.74-$12.24 (+10-15% reported).
- Expects ~$1.5B in share repurchases in 2025 (~4% of market cap), subject to market conditions.
- 2024 full year revenue $3.898B (+6% as reported and organic); targets 200-250 bps operating margin improvement in 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/874716/000110465925008331/0001104659-25-008331-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/874716/000110465925008331/tm255269d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-008331

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer